18th Nov 2016 07:00
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Completion of Sale
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that further to the announcements on 4 October 2016 and 27 October 2016 it has completed the sale of its shareholding in Innovenn UK Limited to Integumen Limited and that Integumen Limited is currently going through an IPO process. Venn is receiving ordinary shares of £1.00 each in Integumen as consideration.
Enquiries:
Venn Life Sciences Holdings Plc | www.vennlifesciences.com | |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 | |
Jonathan Hartshorn, Chief Financial Officer | Tel: +353 153 93 269 | |
Aoife O Farrell, Marketing Manager | Tel: +353 153 93 269 | |
Davy (Nominated Adviser, ESM Adviser and Joint Broker) | Tel: +353 1 679 6363 | |
Fergal Meegan / Matthew DeVere White (Corporate Finance) | ||
Paul Burke (Corporate Broking) | ||
| ||
Hybridan LLP (Joint-Broker) |
| |
Claire Louise Noyce | Tel: 020 3764 2341 | |
| ||
Walbrook PR Ltd | Tel: 020 7933 8787 or [email protected] | |
Paul McManus | Mob: 07980 541 893 | |
Lianne Cawthorne | Mob: 07584 391 303 | |
About Venn Life Sciences: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn Life Sciences specialises in rapid deployment and management of multisite projects, across all phases.
For more information about the Company, please visit: www.vennlifesciences.com
Related Shares:
ORPH.L